Drug profile

The FDA adverse-event record for S-Adenosyl-Methionine (Same) + Silybin

19 FDA reports name S-Adenosyl-Methionine (Same) + Silybin, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1871 of 2,679
by report volume (all drugs)
19
adverse-event reports
15.8%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, S-Adenosyl-Methionine (Same) + Silybin ranks #1827 of 2679 by total reports (19). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1827
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. S-Adenosyl-Methionine (Same) + Silybin has 19 reports now versus 19 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to S-Adenosyl-Methionine (Same) + Silybin changes

Signature read: 19 reports place S-Adenosyl-Methionine (Same) + Silybin in the lower third of FDA AER volume (#1871 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
3
Deaths Reported
15.8%
Death-coded share of reports

Active Ingredients

S-Adenosyl-Methionine (Same) + Silybin

Administration Routes

OralTopical

Species Affected

Dog 19

Most Affected Breeds

Terrier - Boston 2
Poodle - Miniature 2
Shih Tzu 2
Dachshund - Miniature 1
Brittany 1
Schnauzer - Miniature 1
Dog (other) 1
Crossbred Canine/dog 1
Retriever - Golden 1
Chihuahua 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 10
Elevated serum alkaline phosphatase (SAP) 5
Decreased appetite 5
Anorexia 5
Diarrhoea 4
Hyperglycaemia 4
Elevated alanine aminotransferase (ALT) 3
Elevated blood urea nitrogen (BUN) 3
Hyponatremia 3
Elevated liver enzymes 3
Death by euthanasia 3
Underdose 3

Outcome Breakdown

Outcome Unknown
13 (68.4%)
Recovered/Normal
3 (15.8%)
Euthanized
3 (15.8%)

S-Adenosyl-Methionine (Same) + Silybin: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for S-Adenosyl-Methionine (Same) + Silybin (#1871 of 2,679 by report volume); death-coded 15.8%. PlainBreed drug row · report volume stamp 19 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →